Careful evaluation for pre-existing risk factors prior to the initiation of tyrosine kinase inhibitor (TKI) therapy, effective management of risk factors and close monitoring for any adverse events as well as drug interactions of TKIs (with the most commonly used medications, supplements, and fruits/fruit juices) after initiation of TKI therapy are recommended for all patients to mitigate the risk of long-term adverse events. Patients need to be counselled on the potential risk factors or comorbidity that could predispose them to a specific adverse event associated with TKI therapy. In addition, patient education on monitoring and reporting symptoms of an adverse event is also essential for the implementation of effective supportive care interventions. This session provides education on the appropriate strategies that have been evaluated in clinical trials for monitoring and management of adverse events associated with TKI therapy.